AstraZeneca once again responds to the investigation of its executives in China.
On November 5th local time, AstraZeneca's global website released a statement regarding stock price fluctuations, stating that according to policy, the company does not comment on speculative media reports, including those related to ongoing investigations in China. AstraZeneca emphasizes that if requested, it will fully cooperate with Chinese law enforcement agencies. The company will continue to provide drugs to Chinese patients and its business will continue.
On October 30th, the official websites of AstraZeneca Global and China announced that Wang Lei, AstraZeneca Global Executive Vice President, International Business Chairman, and China President, is cooperating with the investigation in China. AstraZeneca China is operating normally under the leadership of the current General Manager. If requested, AstraZeneca will fully cooperate with the investigation.
On November 4th, a reporter from The Paper noticed that the National Enterprise Credit Information Publicity System showed that the person in charge of AstraZeneca Pharmaceutical Co., Ltd. (legal representative, person in charge, chief representative, partnership affairs executor, etc.) had changed from Wang Lei to MAQDOSI EWA, with the change date being October 11, 2024.
On the same day, there were also changes in the market entity type and investors of AstraZeneca Pharmaceuticals Limited. The type of market entity has been changed from a limited liability company (Sino foreign cooperation) to a limited liability company (sole proprietorship of foreign legal persons). The change of investors (including the amount, method, date, and name of the investor) will be changed from Wuxi Xinfa Group Co., Ltd., Jiangsu Wuxi Pharmaceutical Co., Ltd., and AstraZeneca Continent B.V. to AstraZeneca Continent B.V.
As of the close on November 5th, AstraZeneca's US stock fell 7.22% and the UK stock fell 8.4%.